Stockwatch: The Canadian patient
This article was originally published in Scrip
Executive Summary
It has not been a good week for Canadian biotech. The sell-off of the crown jewels at QLT (scripintelligence.com, 25 September 2012), the return of rights to Cardiome (scripintelligence.com, 27 September 2012), the loss of a court case at Tekmira and the failure to receive fast-track NDA status at Aeterna Zentaris have left biotech investors north of the border wondering if there is much of a home-grown sector left.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.